BR9803168A - Tratamento de parada cardìaca congestiva. - Google Patents

Tratamento de parada cardìaca congestiva.

Info

Publication number
BR9803168A
BR9803168A BR9803168-6A BR9803168A BR9803168A BR 9803168 A BR9803168 A BR 9803168A BR 9803168 A BR9803168 A BR 9803168A BR 9803168 A BR9803168 A BR 9803168A
Authority
BR
Brazil
Prior art keywords
treatment
growth hormone
congestive heart
cardiac arrest
administering
Prior art date
Application number
BR9803168-6A
Other languages
English (en)
Inventor
Raymond Francis Kauffman
Alan David Palkowitz
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR9803168A publication Critical patent/BR9803168A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Patente de Invenção: <B>"TRATAMENTO DE PARADA CARDìACA CONGESTIVA"<D>. A invenção provê métodos para a modulação de função cardíaca através da administração de um secretagogo de hormónio de crescimento, que resulta em um aumento nos níveis de hormónio de crescimento endógeno. São também providos processos para o tratamento de insuficiência cardíaca congestiva através da administração de um secretagogo de hormónio de crescimento. São ainda providos processos para o tratamento de insuficiência cardíaca congestiva através da administração de um secretagogo de hormónio de crescimento em combinação com um hormónio de liberação de hormónio de crescimento, ou em combinação com um agente anti-hipertensivo, diurético, ou outros agentes apropriados.
BR9803168-6A 1997-08-19 1998-08-18 Tratamento de parada cardìaca congestiva. BR9803168A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5613597P 1997-08-19 1997-08-19

Publications (1)

Publication Number Publication Date
BR9803168A true BR9803168A (pt) 2000-01-11

Family

ID=22002400

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9803168-6A BR9803168A (pt) 1997-08-19 1998-08-18 Tratamento de parada cardìaca congestiva.

Country Status (7)

Country Link
EP (1) EP0898963A3 (pt)
JP (1) JP2001515045A (pt)
AU (1) AU9471598A (pt)
BR (1) BR9803168A (pt)
CA (1) CA2300848A1 (pt)
WO (1) WO1999008697A1 (pt)
ZA (1) ZA987383B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932548A (en) * 1998-06-03 1999-08-03 Deghenghi; Romano Lysine containing peptides for treatment of heart disease
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
WO2000010565A1 (en) * 1998-08-18 2000-03-02 Eli Lilly And Company Growth hormone secretagogues
CO5160260A1 (es) * 1999-02-19 2002-05-30 Lilly Co Eli Secretagogos de la hormona del crecimiento derivados de imi- dazol 1,4- substituido
US6828331B1 (en) 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
EP1289526A4 (en) 2000-05-30 2005-03-16 Merck & Co Inc MELANOCORTIN RECEPTOR AGONISTS
ES2333097T3 (es) 2000-05-31 2010-02-17 Raqualia Pharma Inc Uso de secretagogos de la hormona de crecimiento para estimular la motilidad gastrointestinal.
AU2001274601A1 (en) 2000-06-23 2002-01-02 Kaken Pharmaceutical Co., Ltd. Preventives or remedies for heart failure
GT200100147A (es) * 2000-07-31 2002-06-25 Derivados de imidazol
US6756385B2 (en) * 2000-07-31 2004-06-29 Pfizer Inc. Imidazole derivatives
US7125840B2 (en) 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
WO2003087069A2 (en) 2002-04-09 2003-10-23 Eli Lilly And Company Dipeptidic growth hormone secretagogues
WO2004014412A1 (ja) * 2002-08-09 2004-02-19 Kaken Pharmaceutical Co., Ltd. 心筋細胞保護剤
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
PL1730119T3 (pl) 2004-03-23 2008-10-31 Pfizer Products Incorporated Związki imidazolowe do leczenia zaburzeń neurodegeneracyjnych
WO2007034326A2 (en) 2005-09-22 2007-03-29 Pfizer Products Inc. Imidazole compounds for the treatment of neurological disorders
US7601844B2 (en) 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
US7615556B2 (en) 2006-01-27 2009-11-10 Bristol-Myers Squibb Company Piperazinyl derivatives as modulators of chemokine receptor activity
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
KR20090107088A (ko) 2007-02-09 2009-10-12 트랜자임 파르마 인크 거대고리 그렐린 수용체 조절제 및 이의 사용 방법
TWI433838B (zh) 2008-06-25 2014-04-11 必治妥美雅史谷比公司 作為趨化因子受體活性調節劑之六氫吡啶衍生物
US8642622B2 (en) 2010-06-16 2014-02-04 Bristol-Myers Squibb Company Piperidinyl compound as a modulator of chemokine receptor activity
US9763957B2 (en) 2013-07-18 2017-09-19 Novartis Ag Autotaxin inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206235A (en) * 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
US5663146A (en) * 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
PL176993B1 (pl) * 1992-12-11 1999-08-31 Merck & Co Inc Nowe związki spiropiperydynowe oraz sposób ich wytwarzania
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5721250A (en) * 1993-12-23 1998-02-24 Merck & Co. Inc. Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
EP0761220A1 (en) * 1995-08-21 1997-03-12 Eli Lilly And Company 2-Acylaminopropanamides as growth hormone secretagogues
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
SE9703929D0 (sv) * 1996-11-22 1997-10-28 Pharmacia & Upjohn Ab Therapeutical use and method

Also Published As

Publication number Publication date
AU9471598A (en) 1999-03-08
EP0898963A3 (en) 2003-07-09
JP2001515045A (ja) 2001-09-18
WO1999008697A1 (en) 1999-02-25
EP0898963A2 (en) 1999-03-03
ZA987383B (en) 2000-02-17
CA2300848A1 (en) 1999-02-25

Similar Documents

Publication Publication Date Title
BR9803168A (pt) Tratamento de parada cardìaca congestiva.
BR9809951A (pt) Método para tratamento da obesidade
BG102022A (en) Metering inhaler for salmetrol
GT199800126A (es) Terapia de combinacion.
CA2250420A1 (en) Combinations of vasopressin and adrenergic agents for the treatment of cardiac arrest
BR0212080A (pt) composto de glp-1, método de estimulação de receptor de glp-1 em um indivìduo necessitando de tal estimulação, e, uso de um composto de glp-1
EA199900553A1 (ru) Чрескожная терапевтическая система
PT831910E (pt) Terapia de combinacao a base de um antagonista epoxi-esteroidal de aldosterona e um antagonista de angiotensina ii para o tratamento de ataque cardiaco congestivo
PT100323A (pt) Dispositivo para a reducao das sensacoes durante a administracao iontoforetica de um agente terapeutico
CO4520286A1 (es) Procedimiento para preparar clorhidrato de 1-(2 -desoxi-2 , 2 -difluoro-d-ribofuranosil)-4-aminopirimidin-2-ona
BR9814923A (pt) Método para tratamento de doença de alzheimer
BR9811094A (pt) Agente terapêutico para tumores linfáticos
ATE239474T1 (de) Verwendung von levobupivacain
ES2193233T3 (es) Uso de amiodipina, una sal de la misma o felodipina en combinacion con un inhibidor ace en la fabricacion de un medicamento para el tratamiento de insuficiencia cardiaca conjuntiva no isquemica.
DE59308848D1 (de) Anwendung von urodilatin bei lungen- und bronchialerkrankungen
DE69821498D1 (de) Verwendung von amifostin
ATE543451T1 (de) Bioabsorbierbare, osteogenetische knochenplatte
WO1999021574A3 (en) Enhancement of morphogen activity
DK578887D0 (da) Antihypertensiva
UA50761C2 (uk) Спосіб запобігання та/або лікування серцевих захворювань, фармацевтична композиція та спосіб запобігання та/або лікування серцевої недостатності та дисфункції шлуночків в організмі теплокровної тварини
BR9713514A (pt) Novo uso de creatina
KR960013383A (ko) 항혈전성 및 피브린용해성 치료제와 조합하여 사용되는 치료제로서의 폰 빌레브란트 인자(vWF)-함유 농축물의 용도
ES2177769T3 (es) Derivado de aminotetralina para la terapia de trastornos cardiovascu lares.
EP0181050A3 (en) 1-b-d-ribofuranosyl-1,2,4-triazole-3-carboxamide for use in medical treatment of humans
BR9710038A (pt) Novas composições e matrizes radiofarmacêuticas e seus usos.

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1894 DE 24/04/2007.